|
| 37973242 | Prostate-Specific Membrane Antigen-Ligand Therapy: What the Radiologist Needs to Know. | Radiol Clin North Am | 2024 |
| 37573199 | Standardized PSMA-PET Imaging of Advanced Prostate Cancer. | Semin Nucl Med | 2024 |
| 36935345 | Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISEÂ V2). | Eur Urol | 2023 |
| 37902861 | Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study. | EJNMMI Res | 2023 |
| 37482512 | Presurgical <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. | Eur Urol | 2023 |
| 38069166 | Comparative Analysis of Morphological and Functional Effects of <sup>225</sup>Ac- and <sup>177</sup>Lu-PSMA Radioligand Therapies (RLTs) on Salivary Glands. | Int J Mol Sci | 2023 |
| 37779132 | Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study. | Eur J Hybrid Imaging | 2023 |
| 37678927 | Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. | J Nucl Med | 2023 |
| 37414701 | Prostate-specific Membrane Antigen Reporting and Data System Version 2.0. | Eur Urol | 2023 |
| 37146173 | FAPI PET Signal in Hibernoma Reflects FAP Expression in Tumor Vasculature Cells. | Clin Nucl Med | 2023 |
| 37037684 | Is There a Role of Artificial Intelligence in Preclinical Imaging? | Semin Nucl Med | 2023 |
| 37432081 | Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) in Metastatic Castration-resistant Prostate Cancer. | Radiology | 2023 |
| 36997329 | PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. | J Nucl Med | 2023 |
| 34255130 | The added value of PSMA PET/MR radiomics for prostate cancer staging. | Eur J Nucl Med Mol Imaging | 2022 |
| 35771265 | Application of machine learning to pretherapeutically estimate dosimetry in men with advanced prostate cancer treated with <sup>177</sup>Lu-PSMA I&T therapy. | Eur J Nucl Med Mol Imaging | 2022 |
| 35767071 | Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. | Eur J Nucl Med Mol Imaging | 2022 |
| 35609224 | Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMAÂ and Beyond. | Am Soc Clin Oncol Educ Book | 2022 |
| 35422442 | Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. | J Nucl Med | 2022 |
| 33602654 | Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. | Eur Urol Oncol | 2022 |
| 35273096 | Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with <sup>177</sup>Lu-PSMA Therapy: A Multicenter Retrospective Analysis. | J Nucl Med | 2022 |
| 34385338 | The Influence of Specific Activity on the Biodistribution of <sup>18</sup>F-rhPSMA-7.3: A Retrospective Analysis of Clinical PET Data. | J Nucl Med | 2022 |
| 34232350 | Whole-body uptake classification and prostate cancer staging in <sup>68</sup>Ga-PSMA-11 PET/CT using dual-tracer learning. | Eur J Nucl Med Mol Imaging | 2022 |
| 34049987 | Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality? | J Nucl Med | 2022 |
| 32725538 | Almost 10Â years of PET/MR attenuation correction: the effect on lesion quantification with PSMA: clinical evaluation on 200 prostate cancer patients. | Eur J Nucl Med Mol Imaging | 2021 |
| 33509974 | The Impact of Monosodium Glutamate on <sup>68</sup>Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study. | J Nucl Med | 2021 |
| 33914106 | <sup>68</sup>Ga-FAPI-46 and <sup>18</sup>F-FDG PET/CT in a patient with immune-related thyroiditis induced by immune checkpoint inhibitors. | Eur J Nucl Med Mol Imaging | 2021 |
| 34902034 | Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. | JAMA Netw Open | 2021 |
| 34016732 | Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with <sup>177</sup>Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort. | J Nucl Med | 2021 |
| 34246328 | Nomograms to predict outcomes after <sup>177</sup>Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. | Lancet Oncol | 2021 |
| 33990403 | PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease. | J Nucl Med | 2021 |
| 33293081 | Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. | Eur Urol | 2021 |
| 32917782 | Identification of PCWG3 Target Populations Is More Accurate and Reproducible with PSMA PET Than with Conventional Imaging: A Multicenter Retrospective Study. | J Nucl Med | 2021 |
| 31253741 | Matched-Pair Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and <sup>18</sup>F-PSMA-1007 PET/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy. | J Nucl Med | 2020 |
| 31813050 | Deep neural network for automatic characterization of lesions on <sup>68</sup>Ga-PSMA-11 PET/CT. | Eur J Nucl Med Mol Imaging | 2020 |
| 31806773 | Mapping Prostate Cancer Lesions Before and After Unsuccessful Salvage Lymph Node Dissection Using Repeat PSMA PET. | J Nucl Med | 2020 |
| 32016584 | Pre-test <sup>68</sup>Ga-PSMA-ligand PET/CT positivity in early biochemical recurrent prostate cancer after radical prostatectomy-validation of a prediction model. | EJNMMI Res | 2020 |
| 33166197 | Joint Imaging Platform for Federated Clinical Data Analytics. | JCO Clin Cancer Inform | 2020 |
| 32111687 | Early Prostate-Specific Antigen Changes and Clinical Outcome After <sup>177</sup>Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer. | J Nucl Med | 2020 |
| 32532512 | Efficacy and Safety of <sup>177</sup>Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. | Eur Urol | 2020 |
| 30442756 | Early Experience of Rechallenge <sup>177</sup>Lu-PSMA Radioligand Therapy After an Initial Good Response in Patients with Advanced Prostate Cancer. | J Nucl Med | 2019 |
| 31946051 | Deep Neural Network for Automatic Characterization of Lesions on 68Ga-PSMA PET/CT Images. | Annu Int Conf IEEE Eng Med Biol Soc | 2019 |
| 31792771 | Evaluation of SUV normalized by lean body mass (SUL) in <sup>68</sup>Ga-PSMA11 PET/CT: a bi-centric analysis. | EJNMMI Res | 2019 |
| 31273434 | Exceptional 4-year response to <sup>177</sup>Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer. | Eur J Nucl Med Mol Imaging | 2019 |
| 31524577 | Reply by Authors. | J Urol | 2019 |
| 31233369 | <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. | J Urol | 2019 |
| 30850484 | qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using <sup>68</sup>Ga-PSMA11 PET/CT. | J Nucl Med | 2019 |
| 30818360 | Voxel based comparison and texture analysis of 18F-FDG and 18F-FMISO PET of patients with head-and-neck cancer. | PLoS One | 2019 |
| 30473431 | Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with <sup>177</sup>Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. | Eur Urol | 2019 |
| 29794224 | One-Stop-Shop Whole-Body <sup>68</sup>Ga-PSMA-11 PET/MRI Compared with Clinical Nomograms for Preoperative T and N Staging of High-Risk Prostate Cancer. | J Nucl Med | 2018 |
| 29432339 | 18F-Choline PET/MR Can Detect and Delineate Local Recurrence After High-Intensity Focused Ultrasound Therapy of Prostate Cancer. | Clin Nucl Med | 2018 |